Bringing Automation To Large-Scale Manufacturing Of TCR Modified T Cells For Adoptive Cell Therapy

Adoptive immunotherapy using gene-modified T cells redirected against cancer has proven clinical efficacy and tremendous potential in several medical fields. However, such personalized medicine faces several challenges in the complexity associated with current clinical manufacturing methods. Conventionally, preparation of autologous gene-modified T cells comprises of many open handling steps, is labor intensive and is not adapted to automatically manufacture large numbers of gene-engineered T cells. Moreover, the cell manufacturing process requires extensive training of personnel as well as dedicated infrastructure, both restrict the widespread use of these clinical procedures.

Discover an automated process that enables the generation of large numbers of gene-engineered T cells for adoptive T cell therapy. This process is suitable for applications where high doses of gene-engineered T cells are meant to be used, such as in TCR-transduced T cells. Furthermore, this new process yields a cell product comparable in respect to cellular composition, T cell subset ratio, and differentiation.